Bionano Genomics

129 articles about Bionano Genomics

• Largest Study of Mendelian Disease Highlights how OGM, alongside other Techniques, May Enhance Success Rates in Identifying Molecular Causes of Genetic Disease

  9/14/2023

  Bionano Genomics, Inc., announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.

• Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric Leukemia

  9/6/2023

  Bionano Genomics, Inc. announced a peer-reviewed publication from researchers at the German Cancer Consortium showing the utility of optical genome mapping and whole-exome sequencing in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia.

• Bionano Announces Publication Demonstrating Utility of OGM as an Alternative to KT and CMA for Evaluating CRISPR-Edited Cells as Part of Stem Cell Therapy Development

  8/30/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic structural alterations that may limit their usefulness for stem cell therapy.

• Bionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health

  8/28/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese original equipment manufacturing (OEM) partner, A-smart MedTech (A-smart), an assisted reproductive technology company, has obtained reagent class I registrations from China's National Medical Products Administration (NMPA) for Bionano's DNA extraction kit and labeling products.

• Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

  8/21/2023

  Bionano Genomics, Inc. announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market.

• Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory

  8/16/2023

  Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.

• Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

  8/14/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023.

• Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting

  8/11/2023

  Bionano Genomics, Inc. announced its participation at the Cancer Genomics Consortium 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping for solid tumor and hematological malignancy cancer research, including scientific platform and poster presentations from Bionano and a panel discussion featuring esteemed researchers from across the cancer genomics landscape.

• Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress

  8/9/2023

  Bionano Genomics, Inc. reported financial results for the second quarter ended June 30, 2023.

• Bionano Genomics Announces Reverse Stock Split - August 04, 2023

  8/4/2023

  Bionano Genomics, Inc. announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

• Bionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023

  8/2/2023

  Bionano Genomics, Inc. announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.

• Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users

  7/31/2023

  Bionano Genomics, Inc. announced the successful launch of its optical genome mapping roadshow, Bionano TOUR, a series of regional customer-led events that showcase the latest advancements to the OGM workflow and demonstrate applicable research applications.

• Bionano to Present at the Canaccord Genuity 43rd Annual Growth Conference

  7/27/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.

• Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies

  6/29/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the Stratys™ system for high throughput optical genome mapping (OGM) and VIA™ software for visualization, interpretation and reporting of genome analysis for OGM, microarrays and next-generation sequencing (NGS) data in one integrated software platform.

• Bionano to Present at the Healthcare Virtual Conference

  6/21/2023

  Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.

• Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers

  6/20/2023

  Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.

• Bionano Announces Results from its Annual Meeting of Stockholders - June 14, 2023

  6/14/2023

  Bionano Genomics, Inc. announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting.

• Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting

  6/13/2023

  Bionano Genomics, Inc. announced its participation in the International Society for Stem Cell Research Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping for research, development, and manufacturing applications in stem cell therapy.

• Bionano Announces 2023 Winners of its Innovator Research Grant Program

  6/12/2023

  Bionano Genomics, Inc. announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr. Michael Khodadoust at Stanford University.

• Bionano Announces Extensive Lineup of Content at European Conferences Featuring OGM Utility Across a Broad Range of Research Applications

  6/8/2023

  Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the company’s robust presence at key European cytogenetic conferences, including the European Hematology Association (EHA) 2023 Congress, the European Human Genetics (ESHG) 2023 Conference and the European Association for Cancer Research (EACR) 2023 Congress.